Loading…

In vitro stability and permeability studies of liposomal delivery systems for a novel lipophilic endomorphin 1 analogue

We have previously shown that the stability and permeability of peptides can be greatly improved by conjugation with lipoamino acids such as 2-aminododecanoic acid (C12Laa). However, the increase in lipophilicity which this conjugation provides can also cause a significant decrease in the compound&#...

Full description

Saved in:
Bibliographic Details
Published in:International journal of pharmaceutics 2008-05, Vol.356 (1), p.37-43
Main Authors: Koda, Yasuko, Liang, Ming Tao, Blanchfield, Joanne T., Toth, Istvan
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c393t-f32e4d9df85614fceb75e202e3547b296e20cd0cfca684526a6b0047a758dad73
cites cdi_FETCH-LOGICAL-c393t-f32e4d9df85614fceb75e202e3547b296e20cd0cfca684526a6b0047a758dad73
container_end_page 43
container_issue 1
container_start_page 37
container_title International journal of pharmaceutics
container_volume 356
creator Koda, Yasuko
Liang, Ming Tao
Blanchfield, Joanne T.
Toth, Istvan
description We have previously shown that the stability and permeability of peptides can be greatly improved by conjugation with lipoamino acids such as 2-aminododecanoic acid (C12Laa). However, the increase in lipophilicity which this conjugation provides can also cause a significant decrease in the compound's water solubility. In this study, we coupled C12Laa to the N-terminus of endomorphin1 (Endo-1, Tyr-Pro-Trp-Phe-NH 2), and addressed its solubility issue by formulating C12Laa-Endo-1 into phosphatidylcholine liposomes. The aqueous solubility of the lipidic analogue was greatly improved, facilitating the accurate analysis of the compound in in vitro assays. The metabolic stability and in vitro endothelial permeability of the C12Laa-Endo-1 liposomal formulation was assessed using Caco-2 cells, and compared with the formulation of the parent peptide Endo-1. The liposome-encapsulated C12Laa-Endo exhibited significant increases in both stability and permeability. These results suggest that the combination of chemical modification and liposome formulation has great potentials in improving the bioavailability of neuroactive peptides.
doi_str_mv 10.1016/j.ijpharm.2007.12.036
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_69155751</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0378517307010757</els_id><sourcerecordid>69155751</sourcerecordid><originalsourceid>FETCH-LOGICAL-c393t-f32e4d9df85614fceb75e202e3547b296e20cd0cfca684526a6b0047a758dad73</originalsourceid><addsrcrecordid>eNqFkE1v1DAQhi0EokvhJ4B8gVuCP2I7e0KoAlqpEhc4W449pl45cbCTRfvv8bKBHjlZ43nemdGD0GtKWkqofH9ow2F-MHlsGSGqpawlXD5BO9or3vBOyadoR7jqG0EVv0IvSjkQQiSj_Dm6oj1TjBO5Q7_uJnwMS064LGYIMSwnbCaHZ8gj_P0oy-oCFJw8jmFOJY0mYgcxHCHX7qksMBbsU8YGT-kI8Q82P9S0xTC5NKZcqwnTOtvE9GOFl-iZN7HAq-29Rt8_f_p2c9vcf_1yd_PxvrF8z5fGcwad2zvfC0k7b2FQAhhhwEWnBraXtbCOWG-N7DvBpJEDIZ0ySvTOOMWv0bvL3DmnnyuURY-hWIjRTJDWouWeCqEEraC4gDanUjJ4PecwmnzSlOizcX3Qm3F9Nq4p09V4zb3ZFqzDCO4xtSmuwNsNMMWa6LOZbCj_OEZ4V9kz9-HCQdVxDJB1sQEmCy5ksIt2KfznlN9oVqRY</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>69155751</pqid></control><display><type>article</type><title>In vitro stability and permeability studies of liposomal delivery systems for a novel lipophilic endomorphin 1 analogue</title><source>Elsevier</source><creator>Koda, Yasuko ; Liang, Ming Tao ; Blanchfield, Joanne T. ; Toth, Istvan</creator><creatorcontrib>Koda, Yasuko ; Liang, Ming Tao ; Blanchfield, Joanne T. ; Toth, Istvan</creatorcontrib><description>We have previously shown that the stability and permeability of peptides can be greatly improved by conjugation with lipoamino acids such as 2-aminododecanoic acid (C12Laa). However, the increase in lipophilicity which this conjugation provides can also cause a significant decrease in the compound's water solubility. In this study, we coupled C12Laa to the N-terminus of endomorphin1 (Endo-1, Tyr-Pro-Trp-Phe-NH 2), and addressed its solubility issue by formulating C12Laa-Endo-1 into phosphatidylcholine liposomes. The aqueous solubility of the lipidic analogue was greatly improved, facilitating the accurate analysis of the compound in in vitro assays. The metabolic stability and in vitro endothelial permeability of the C12Laa-Endo-1 liposomal formulation was assessed using Caco-2 cells, and compared with the formulation of the parent peptide Endo-1. The liposome-encapsulated C12Laa-Endo exhibited significant increases in both stability and permeability. These results suggest that the combination of chemical modification and liposome formulation has great potentials in improving the bioavailability of neuroactive peptides.</description><identifier>ISSN: 0378-5173</identifier><identifier>EISSN: 1873-3476</identifier><identifier>DOI: 10.1016/j.ijpharm.2007.12.036</identifier><identifier>PMID: 18272306</identifier><identifier>CODEN: IJPHDE</identifier><language>eng</language><publisher>Amsterdam: Elsevier B.V</publisher><subject>Analgesics, Opioid - chemical synthesis ; Analgesics, Opioid - chemistry ; Analgesics, Opioid - pharmacokinetics ; Biological and medical sciences ; Biological Availability ; Caco-2 Cells ; Drug delivery ; Drug Delivery Systems ; Drug Stability ; Endomorphin ; General pharmacology ; Humans ; Hydrophobic and Hydrophilic Interactions ; Lipopeptide ; Liposomes ; Medical sciences ; Oligopeptides - chemical synthesis ; Oligopeptides - chemistry ; Oligopeptides - pharmacokinetics ; Opioid peptide delivery ; Permeability ; Pharmaceutical technology. Pharmaceutical industry ; Pharmacology. Drug treatments ; Phosphatidylcholines - chemistry ; Solubility</subject><ispartof>International journal of pharmaceutics, 2008-05, Vol.356 (1), p.37-43</ispartof><rights>2008 Elsevier B.V.</rights><rights>2008 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c393t-f32e4d9df85614fceb75e202e3547b296e20cd0cfca684526a6b0047a758dad73</citedby><cites>FETCH-LOGICAL-c393t-f32e4d9df85614fceb75e202e3547b296e20cd0cfca684526a6b0047a758dad73</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27900,27901</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=20341826$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18272306$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Koda, Yasuko</creatorcontrib><creatorcontrib>Liang, Ming Tao</creatorcontrib><creatorcontrib>Blanchfield, Joanne T.</creatorcontrib><creatorcontrib>Toth, Istvan</creatorcontrib><title>In vitro stability and permeability studies of liposomal delivery systems for a novel lipophilic endomorphin 1 analogue</title><title>International journal of pharmaceutics</title><addtitle>Int J Pharm</addtitle><description>We have previously shown that the stability and permeability of peptides can be greatly improved by conjugation with lipoamino acids such as 2-aminododecanoic acid (C12Laa). However, the increase in lipophilicity which this conjugation provides can also cause a significant decrease in the compound's water solubility. In this study, we coupled C12Laa to the N-terminus of endomorphin1 (Endo-1, Tyr-Pro-Trp-Phe-NH 2), and addressed its solubility issue by formulating C12Laa-Endo-1 into phosphatidylcholine liposomes. The aqueous solubility of the lipidic analogue was greatly improved, facilitating the accurate analysis of the compound in in vitro assays. The metabolic stability and in vitro endothelial permeability of the C12Laa-Endo-1 liposomal formulation was assessed using Caco-2 cells, and compared with the formulation of the parent peptide Endo-1. The liposome-encapsulated C12Laa-Endo exhibited significant increases in both stability and permeability. These results suggest that the combination of chemical modification and liposome formulation has great potentials in improving the bioavailability of neuroactive peptides.</description><subject>Analgesics, Opioid - chemical synthesis</subject><subject>Analgesics, Opioid - chemistry</subject><subject>Analgesics, Opioid - pharmacokinetics</subject><subject>Biological and medical sciences</subject><subject>Biological Availability</subject><subject>Caco-2 Cells</subject><subject>Drug delivery</subject><subject>Drug Delivery Systems</subject><subject>Drug Stability</subject><subject>Endomorphin</subject><subject>General pharmacology</subject><subject>Humans</subject><subject>Hydrophobic and Hydrophilic Interactions</subject><subject>Lipopeptide</subject><subject>Liposomes</subject><subject>Medical sciences</subject><subject>Oligopeptides - chemical synthesis</subject><subject>Oligopeptides - chemistry</subject><subject>Oligopeptides - pharmacokinetics</subject><subject>Opioid peptide delivery</subject><subject>Permeability</subject><subject>Pharmaceutical technology. Pharmaceutical industry</subject><subject>Pharmacology. Drug treatments</subject><subject>Phosphatidylcholines - chemistry</subject><subject>Solubility</subject><issn>0378-5173</issn><issn>1873-3476</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><recordid>eNqFkE1v1DAQhi0EokvhJ4B8gVuCP2I7e0KoAlqpEhc4W449pl45cbCTRfvv8bKBHjlZ43nemdGD0GtKWkqofH9ow2F-MHlsGSGqpawlXD5BO9or3vBOyadoR7jqG0EVv0IvSjkQQiSj_Dm6oj1TjBO5Q7_uJnwMS064LGYIMSwnbCaHZ8gj_P0oy-oCFJw8jmFOJY0mYgcxHCHX7qksMBbsU8YGT-kI8Q82P9S0xTC5NKZcqwnTOtvE9GOFl-iZN7HAq-29Rt8_f_p2c9vcf_1yd_PxvrF8z5fGcwad2zvfC0k7b2FQAhhhwEWnBraXtbCOWG-N7DvBpJEDIZ0ySvTOOMWv0bvL3DmnnyuURY-hWIjRTJDWouWeCqEEraC4gDanUjJ4PecwmnzSlOizcX3Qm3F9Nq4p09V4zb3ZFqzDCO4xtSmuwNsNMMWa6LOZbCj_OEZ4V9kz9-HCQdVxDJB1sQEmCy5ksIt2KfznlN9oVqRY</recordid><startdate>20080522</startdate><enddate>20080522</enddate><creator>Koda, Yasuko</creator><creator>Liang, Ming Tao</creator><creator>Blanchfield, Joanne T.</creator><creator>Toth, Istvan</creator><general>Elsevier B.V</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20080522</creationdate><title>In vitro stability and permeability studies of liposomal delivery systems for a novel lipophilic endomorphin 1 analogue</title><author>Koda, Yasuko ; Liang, Ming Tao ; Blanchfield, Joanne T. ; Toth, Istvan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c393t-f32e4d9df85614fceb75e202e3547b296e20cd0cfca684526a6b0047a758dad73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Analgesics, Opioid - chemical synthesis</topic><topic>Analgesics, Opioid - chemistry</topic><topic>Analgesics, Opioid - pharmacokinetics</topic><topic>Biological and medical sciences</topic><topic>Biological Availability</topic><topic>Caco-2 Cells</topic><topic>Drug delivery</topic><topic>Drug Delivery Systems</topic><topic>Drug Stability</topic><topic>Endomorphin</topic><topic>General pharmacology</topic><topic>Humans</topic><topic>Hydrophobic and Hydrophilic Interactions</topic><topic>Lipopeptide</topic><topic>Liposomes</topic><topic>Medical sciences</topic><topic>Oligopeptides - chemical synthesis</topic><topic>Oligopeptides - chemistry</topic><topic>Oligopeptides - pharmacokinetics</topic><topic>Opioid peptide delivery</topic><topic>Permeability</topic><topic>Pharmaceutical technology. Pharmaceutical industry</topic><topic>Pharmacology. Drug treatments</topic><topic>Phosphatidylcholines - chemistry</topic><topic>Solubility</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Koda, Yasuko</creatorcontrib><creatorcontrib>Liang, Ming Tao</creatorcontrib><creatorcontrib>Blanchfield, Joanne T.</creatorcontrib><creatorcontrib>Toth, Istvan</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of pharmaceutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Koda, Yasuko</au><au>Liang, Ming Tao</au><au>Blanchfield, Joanne T.</au><au>Toth, Istvan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>In vitro stability and permeability studies of liposomal delivery systems for a novel lipophilic endomorphin 1 analogue</atitle><jtitle>International journal of pharmaceutics</jtitle><addtitle>Int J Pharm</addtitle><date>2008-05-22</date><risdate>2008</risdate><volume>356</volume><issue>1</issue><spage>37</spage><epage>43</epage><pages>37-43</pages><issn>0378-5173</issn><eissn>1873-3476</eissn><coden>IJPHDE</coden><abstract>We have previously shown that the stability and permeability of peptides can be greatly improved by conjugation with lipoamino acids such as 2-aminododecanoic acid (C12Laa). However, the increase in lipophilicity which this conjugation provides can also cause a significant decrease in the compound's water solubility. In this study, we coupled C12Laa to the N-terminus of endomorphin1 (Endo-1, Tyr-Pro-Trp-Phe-NH 2), and addressed its solubility issue by formulating C12Laa-Endo-1 into phosphatidylcholine liposomes. The aqueous solubility of the lipidic analogue was greatly improved, facilitating the accurate analysis of the compound in in vitro assays. The metabolic stability and in vitro endothelial permeability of the C12Laa-Endo-1 liposomal formulation was assessed using Caco-2 cells, and compared with the formulation of the parent peptide Endo-1. The liposome-encapsulated C12Laa-Endo exhibited significant increases in both stability and permeability. These results suggest that the combination of chemical modification and liposome formulation has great potentials in improving the bioavailability of neuroactive peptides.</abstract><cop>Amsterdam</cop><pub>Elsevier B.V</pub><pmid>18272306</pmid><doi>10.1016/j.ijpharm.2007.12.036</doi><tpages>7</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0378-5173
ispartof International journal of pharmaceutics, 2008-05, Vol.356 (1), p.37-43
issn 0378-5173
1873-3476
language eng
recordid cdi_proquest_miscellaneous_69155751
source Elsevier
subjects Analgesics, Opioid - chemical synthesis
Analgesics, Opioid - chemistry
Analgesics, Opioid - pharmacokinetics
Biological and medical sciences
Biological Availability
Caco-2 Cells
Drug delivery
Drug Delivery Systems
Drug Stability
Endomorphin
General pharmacology
Humans
Hydrophobic and Hydrophilic Interactions
Lipopeptide
Liposomes
Medical sciences
Oligopeptides - chemical synthesis
Oligopeptides - chemistry
Oligopeptides - pharmacokinetics
Opioid peptide delivery
Permeability
Pharmaceutical technology. Pharmaceutical industry
Pharmacology. Drug treatments
Phosphatidylcholines - chemistry
Solubility
title In vitro stability and permeability studies of liposomal delivery systems for a novel lipophilic endomorphin 1 analogue
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-24T08%3A05%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=In%20vitro%20stability%20and%20permeability%20studies%20of%20liposomal%20delivery%20systems%20for%20a%20novel%20lipophilic%20endomorphin%201%20analogue&rft.jtitle=International%20journal%20of%20pharmaceutics&rft.au=Koda,%20Yasuko&rft.date=2008-05-22&rft.volume=356&rft.issue=1&rft.spage=37&rft.epage=43&rft.pages=37-43&rft.issn=0378-5173&rft.eissn=1873-3476&rft.coden=IJPHDE&rft_id=info:doi/10.1016/j.ijpharm.2007.12.036&rft_dat=%3Cproquest_cross%3E69155751%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c393t-f32e4d9df85614fceb75e202e3547b296e20cd0cfca684526a6b0047a758dad73%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=69155751&rft_id=info:pmid/18272306&rfr_iscdi=true